The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease (P1-3.003)
To report the initial findings up to 36 months from the ongoing Clarity AD open-label extension (OLE) study.
Authors
- Shobha Dhadda (ORCID: https://orcid.org/0000-0002-7290-7168)
- Steven M. Hersch (ORCID: https://orcid.org/0000-0001-5948-6672)
- Larisa Reyderman
- David Li (ORCID: https://orcid.org/0000-0002-6401-4263)
- Michael C. Irizarry (ORCID: https://orcid.org/0000-0002-0246-2511)
- Lynn D. Kramer
- Christopher van Dyck
Institutions
- Yale University (US)
- Eisai (Japan) (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211489
- Citations
- 2
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 3.01